ArticleAnnals of surgical oncology2018
Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study.
Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Prognostic significance of pretreatment systemic immune-inflammation index (SII) in patients with cervical cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: a meta-analysis.Systematic reviews · 2025Pooled it
- Prognostic significance of platelet lymphocyte ratio in patients with melanoma: A meta-analysis.Medicine · 2021Pooled it
- Prognostic and clinicopathological significance of the platelet-to-lymphocyte ratio in melanoma: A meta-analysis involving 2099 patients.The Kaohsiung journal of medical sciences · 2021Pooled it
- Prognostic Value of the Platelet-to-Lymphocyte Ratio in Patients With Melanoma: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- An Itch Receptor Drives Melanoma.bioRxiv : the preprint server for biology · 2026Article
- Systemic immune-inflammation index and pan-immune value as prognostic indicators of clinical outcomes in mycosis fungoides: A retrospective cohort study.British journal of haematology · 2025Article
- A Cross-Sectional Study of Platelet-to-Lymphocyte Ratio in Relation to Pigment Cell Nevi and Atypical Mole Syndrome.Health science reports · 2025Article
- The neutrophil-to-lymphocyte ratio and the prevalence of cutaneous melanoma: a retrospective observational study of NHANES statistics spanning 1999 to 2018.Archives of dermatological research · 2025Observational
- The post-orchiectomy systemic inflammatory index is associated with tumor characteristics in clinical stage I germ cell tumors.Frontiers in oncology · 2025Article
- The causal relationships of granulocytes and melanoma skin cancer: A univariable and multivariable Mendelian randomization study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Prognostic Value of the Neutrophil-to-lymphocyte Ratio, Platelet-to- lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Melanoma Patients: A Cohort Study.Acta dermato-venereologica · 2024Article
- Spectrum of malignant and premalignant skin lesions in 505 adult subjects at risk of skin cancers.BMC cancer · 2024Article
- Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors.Biomedicines · 2023Article
- Article
- Article
- The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy.Journal of cancer research and clinical oncology · 2022Article
- Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma-Persistent Updating.Journal of personalized medicine · 2022Review
- Article
- The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor.Journal of neuro-oncology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundIn the peripheral blood, the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) change in response to malignancy. These biomarkers are associated with adverse outcomes in numerous cancers, but the evidence is limited in relation to melanoma. This study sought to investigate the association between these biomarkers and survival in Stages I-III cutaneous melanoma.
methodsThis multicenter cohort study investigated a consecutive series of patients who underwent wide excision of biopsy-proven cutaneous melanoma and sentinel lymph node biopsy during a 10-year period. The baseline NLR and PLR were calculated immediately before sentinel lymph node biopsy. Adjusted hazard ratios (HRs) for overall and melanoma-specific survival were generated.
resultsOverall, 1351 patients were included in the study. During surveillance, 184 of these patients died (14%), with 141 of the deaths (77%) attributable to melanoma. Worse overall survival was associated with a baseline NLR lower than 2.5 [HR 2.2; 95% confidence interval (CI) 2.0 to 2.3; p < 0.001] and a baseline PLR lower than 100 (HR 1.8; 95% CI 1.7 to 1.8; p < 0.001). Melanoma-specific survival also was worse, with a baseline NLR lower than 2.5 (HR 1.9; 95% CI 1.6 to 2.2; p < 0.001) and a baseline PLR lower than 100 (HR 1.9; 95% CI 1.7 to 2.2; p < 0.001). The 5-year survival for patients with sentinel lymph node metastases and a low NLR and PLR was approximately 50%.
conclusionThis study provides important new data on biomarkers in early-stage melanoma, which contrast with biomarker profiles in advanced disease. These biomarkers may represent the host inflammatory response to melanoma and therefore could help select patients for adjuvant therapy and enhanced surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.